| abstract |
a phospholipid creatinine (PI) 3-kinase inhibitor compound, a pharmaceutically acceptable salt thereof and a prodrug thereof; a composition of the novel compound, either alone or in combination with at least one other therapeutic agent, and pharmaceutically acceptable And a novel compound, whether alone or in combination with at least one other therapeutic agent, for the prevention or treatment of a proliferative disease characterized by growth factors, protein serine/threonine kinase and phosphatidykinase Abnormal activity. |